title: Anti-glutamate receptor 2 as a new potential diagnostic probe for prostatic adenocarcinoma:  a pilot immunohistochemical study.
abstract: Diagnoses of prostatic carcinoma (PC) have increased with widespread screening. While the use of α-methylacyl coA racemase and high molecular weight cytokeratins have aided in distinguishing benign mimics from malignancy, their sensitivity and specificity are limited. We studied 6C4, a monoclonal antibody to glutamate receptor 2, an excitatory amino acid receptor subunit distributed throughout the central nervous system, on benign prostatic epithelium, high-grade prostatic intraepithelial neoplasia, and PC. Ten cases with post-atrophic or adenosis-like prostate glands were also stained with prostatic intraepithelial neoplasia 4, an immunostain cocktail against α-methylacyl coA racemase, p63, and high molecular weight cytokeratin, in parallel with 6C4. Immunoreactivity for 6C4 was graded as negative (0% to 10%), +1 (11%% to 50%), and +2 (>50%). Malignant epithelium was classified by Gleason patterns. Gleason patterns 4 and 5 were subdivided into cribriform or noncribriform type. Its utility in distinguishing postatrophic or adenosis-like glands from prostate cancer, both of which show absence of basal cells on prostatic intraepithelial neoplasia 4 immunostain, was also investigated. Our results revealed a statistically significant difference in staining of benign secretory prostatic epithelium, high-grade prostatic intraepithelial neoplasia, and low Gleason pattern carcinomas. The results also showed 6C4 is a sensitive marker in separating basal cell negative postatrophic or adenosis-like glands from prostate carcinoma. In addition, there was a statistically significant difference between staining of cribriform versus noncribriform Gleason pattern 4 and 5 carcinomas. A limited number of lymph node metastases from cribriform and noncribriform carcinomas were studied, and they stained the same as the primary tumor in the majority of cases. In conclusion, our preliminary data demonstrated potential utility of 6C4 in the pathologic evaluation of PC.
authors.affiliation: Department of Pathology, Mount Sinai School of Medicine, New York, NY, USA. jaclyn.hechtman@mountsinai.org
authors.forename: Jaclyn F
authors.initials: JF
authors.lastname: Hechtman
authors.forename: Guang Q
authors.initials: GQ
authors.lastname: Xiao
authors.forename: Pamela D
authors.initials: PD
authors.lastname: Unger
authors.forename: Yayoi
authors.initials: Y
authors.lastname: Kinoshita
authors.forename: James H
authors.initials: JH
authors.lastname: Godbold
authors.forename: David E
authors.initials: DE
authors.lastname: Burstein
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000473:pathology; D000911:Antibodies, Monoclonal / Q000378:metabolism; D003937:Diagnosis, Differential; D018450:Disease Progression; D005240:Feasibility Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008297:Male; D015335:Molecular Probes / Q000378:metabolism; D060787:Neoplasm Grading; D010865:Pilot Projects; D011467:Prostate / Q000473:pathology; D019048:Prostatic Intraepithelial Neoplasia / Q000175:diagnosis* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology; D018091:Receptors, AMPA / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D012680:Sensitivity and Specificity; D019459:Urothelium / Q000276:immunology / Q000378:metabolism* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D015335:Molecular Probes; D018091:Receptors, AMPA; C104722:glutamate receptor ionotropic, AMPA 2